MMSC 423 - Final Exam with
| | | | | |
verified answers |
Interpret, |calculate, |and |state |the |therapeutic |range |of |the |INR |- |correct |answersINR |= |(patient
|PT |÷ |mean |lab |PT)^ISI
Therapeutic |Range |: |2.0-3.0
Calculate |the |MCV, |MCH, |MCHC |given |pertinent |data |- |correct |answersMCV |(fL) |= |hematocrit |
× |10 |÷ |RBCs
MCH |(pg) |= |hemoglobin |× |10 |÷ |RBCs
MCHC |(%) |= |hemoglobin |× |100 |÷ |hematocrit
Identify |each |coagulation |factor |with |its |proper |name |- |correct |answersI |: |Fibrinogen
II |: |Prothrombin |
III |: |Tissue |factor |
IV |: |Ionic |Calcium |
V |: |Labile |factor |
VII |: |Stable |factor |
VIII |: |Antihemophilic |factor |
vWF |: |von |Willebrand |factor
IX |: |Christmas |factor |
X |: |Stuart-Prower |factor |
XI |: |Plasma |thromboplastin |antecedent |
XII |: |Hageman |factor |
pre-K |: |Prekallikrein; |Fletcher |factor |
HMWK |: |Fitzgerald |factor |; |High-molecular-weight |kininogen |
, XIII |: |Fibrin-stabilizing |factor |(FSF)
PF3 |: |Platelet |factor |3; |phospholipids, |phosphatidyl-serine
Calculate |an |absolute |lymphocyte |count |given |pertinent |data |- |correct |
answersLymphocytes(%) |× |total |WBC
Ex. |lymphocytes |= |39.4%, |WBC |= |7.1x10^9/L
0.394% |× |7.1x10^9/L |= |2.8x10^9/L
Distinguish |among |the |following |laboratory |tests |of |Hemostasis |as |pertaining |to |principle, |
sample |requirements, |reagents |used, |purpose |of |the |tests, |interpretation |of |results: |Bleeding |
Time, |TEG, |PT, |APTT, |Thrombin |Time, |D-Dimer, |Anti-Xa, |PlateletWorks, |Fibrinogen |assay, |
Platelet |aggregometry |- |correct |answers...
Distinguish |the |following |laboratory |test |of |Hemostasis |as |pertaining |to |principle, |sample |
requirements, |reagents |used, |purpose |of |the |tests, |interpretation |of |results: |PFA-100 |- |correct |
answersPrinciple |: |Platelet |Function |Assay; |whole |blood |passes |through |cartridges |until |
activation |by |agonist |causes |occlusion |generating |Closure |Time |(CT)
Sample |requirements |: |800 |μL |whole |blood |per |cartridge |
Reagents |: |Collagen |& |Epinephrine |cartridge |detects |platelet |dysfunction |induced |by |vWD, |
intrinsic |defect, |& |platelet |inhibiting |agents |
Collagen |& |ADP |cartridge |indicates |abnormal |effects |by |aspirin |or |acetylsalicylic |acid |
Purpose |: |Screening |test |of |platelets |that |measures |adhesion |and |aggregation |of |primary |
hemostasis |
Presumptive |diagnosis |for |platelet |function |deficiency, |vWD |& |efficacy |of |aspirin |
| | | | | |
verified answers |
Interpret, |calculate, |and |state |the |therapeutic |range |of |the |INR |- |correct |answersINR |= |(patient
|PT |÷ |mean |lab |PT)^ISI
Therapeutic |Range |: |2.0-3.0
Calculate |the |MCV, |MCH, |MCHC |given |pertinent |data |- |correct |answersMCV |(fL) |= |hematocrit |
× |10 |÷ |RBCs
MCH |(pg) |= |hemoglobin |× |10 |÷ |RBCs
MCHC |(%) |= |hemoglobin |× |100 |÷ |hematocrit
Identify |each |coagulation |factor |with |its |proper |name |- |correct |answersI |: |Fibrinogen
II |: |Prothrombin |
III |: |Tissue |factor |
IV |: |Ionic |Calcium |
V |: |Labile |factor |
VII |: |Stable |factor |
VIII |: |Antihemophilic |factor |
vWF |: |von |Willebrand |factor
IX |: |Christmas |factor |
X |: |Stuart-Prower |factor |
XI |: |Plasma |thromboplastin |antecedent |
XII |: |Hageman |factor |
pre-K |: |Prekallikrein; |Fletcher |factor |
HMWK |: |Fitzgerald |factor |; |High-molecular-weight |kininogen |
, XIII |: |Fibrin-stabilizing |factor |(FSF)
PF3 |: |Platelet |factor |3; |phospholipids, |phosphatidyl-serine
Calculate |an |absolute |lymphocyte |count |given |pertinent |data |- |correct |
answersLymphocytes(%) |× |total |WBC
Ex. |lymphocytes |= |39.4%, |WBC |= |7.1x10^9/L
0.394% |× |7.1x10^9/L |= |2.8x10^9/L
Distinguish |among |the |following |laboratory |tests |of |Hemostasis |as |pertaining |to |principle, |
sample |requirements, |reagents |used, |purpose |of |the |tests, |interpretation |of |results: |Bleeding |
Time, |TEG, |PT, |APTT, |Thrombin |Time, |D-Dimer, |Anti-Xa, |PlateletWorks, |Fibrinogen |assay, |
Platelet |aggregometry |- |correct |answers...
Distinguish |the |following |laboratory |test |of |Hemostasis |as |pertaining |to |principle, |sample |
requirements, |reagents |used, |purpose |of |the |tests, |interpretation |of |results: |PFA-100 |- |correct |
answersPrinciple |: |Platelet |Function |Assay; |whole |blood |passes |through |cartridges |until |
activation |by |agonist |causes |occlusion |generating |Closure |Time |(CT)
Sample |requirements |: |800 |μL |whole |blood |per |cartridge |
Reagents |: |Collagen |& |Epinephrine |cartridge |detects |platelet |dysfunction |induced |by |vWD, |
intrinsic |defect, |& |platelet |inhibiting |agents |
Collagen |& |ADP |cartridge |indicates |abnormal |effects |by |aspirin |or |acetylsalicylic |acid |
Purpose |: |Screening |test |of |platelets |that |measures |adhesion |and |aggregation |of |primary |
hemostasis |
Presumptive |diagnosis |for |platelet |function |deficiency, |vWD |& |efficacy |of |aspirin |
